Peijia Medical is a global service provider of innovative medical solutions. Adhering to the corporate vision of "Devoted to Heart, Reverence for Life", Peijia Medical strives to be a respected global high-tech medical enterprise. Staying true to our original values, we are fully focused on serving patients by providing safe, effective and affordable products and solutions. With continuous innovation, we aim to alleviate the suffering of patients and improve their quality of life. Peijia Medical, headquartered in Suzhou, Jiangsu Province, China, was established in 2012 and listed on the Main Board of the Hong Kong Stock Exchange in May 2020 (Stock Code: 9996. HK).
With the strategic layout of "Innovation-oriented, Simultaneous Treatment of Heart and Cerebrovascular Diseases" and focusing on the innovation, R&D and production of high-end medical devices for structural heart and cerebrovascular disease intervention, Peijia Medical covers the entire product pipeline for aortic, mitral and tricuspid valve replacements and surgical instruments and accessories, as well as diseases related to hemorrhage, ischemia and access in the field of cerebrovascular intervention. The Company's three generations of TAVR system have been approved by the National Medical Products Administration of the People’s Republic of China as innovative medical devices.
With a global outlook, Peijia Medical has set up innovation centers and R&D centers in the United States, Canada, France and other countries to carry out cutting-edge technology research and product development. With its unique comparative advantages in biomaterials processing technology, precision production capacity, quality management system and patent portfolio, Peijia Medical provides products to about 2,000 hospitals through its GMP-compliant high-end medical device production (R&D) bases established in Suzhou, China.
The Company was incorporated in Zhangjiang Hi-Tech Park, Shanghai.
The Company settled in Suzhou Industrial Park.
The Company completed our Series A funding.
The Company started the multi-center confirmatory clinical trial in China for TaurusOne®.
Achieva Medical became our subsidiary through a share swap agreement.
The Company completed our Series B and C funding.
The Company obtained the NMPA Registration Certificate for our Yibida® Guiding Catheter.
The Company launched sales of our second-generation Presgo® Mechanical Detachable Coil.
The Company initiated the clinical trial for TaurusElite®, our second-generation TAVR device.
On May 15, the Company was listed on the Main Board of The Stock Exchange of Hong Kong Limited (Stock Code: 9996. HK)
The Company received a confirmation letter from the National Medical Products Administration of the People’s Republic of China confirming its acceptance of the registration application for TaurusOne®
The Company successfully completed staged animal experimentation for mitral valve edge-to-edge repair.
The Company signed a license and technology transfer agreement with HighLife for transseptal mitral valve replacement products.
The Company obtained NMPA's approval for SacSpeed® and Tethys®.
The Company obtained the Contract Manufacturing License to manufacture under the Jiangsu Pilot Marketing Authorization Holder (MAH) System.
The Company was formally incorporated into the Hang Seng Composite Index and was listed on the Hong Kong Stock Connect.
The Company obtained NMPA's approval for TaurusOne® and TaurusElite®.
The Company started a multi-center clinical trial of the TaurusNXT® Transcatheter Aortic Valve Replacement System.
The Company completed the enrollment of the first subject for the First-in-human clinical trial of the TaurusWave® Lithotripsy Valvuloplasty System.
The Company signed a cooperation development agreement with the U.S. company inQB8 Medical Technologies for transcatheter tricuspid valve replacements (TTVR).
The Company obtained NMPA's approval for Jasper® SS Intracranial Electrolytic Detachable Coil.、
The Company's Global Headquarters Base settled in Suzhou Industrial Park.
The Company proposed the establishment of the Interventional Medtech Institute, an Industrial Research Institute in Suzhou.
The Company signed an exclusive license and technology transfer agreement with JenaValve Technology for TAVR products for aortic regurgitation.
The Company obtained NMPA's approval for Syphonet® Stent Retriever、Tethys AS® Aspiration Catheter and Fastunnel® Delivery Balloon Dilation Catheter .
The Company's TaurusNXT® Transcatheter Aortic Valve Replacement System and HighLife® TSMVR were approved by the NMPA as an innovative medical device.
The Company completed the the First-in-human clinical trial of the HighLife® TSMVR and GeminiOne TEER.
JenaValve Trilogy successfully implanted for the first time in Asia at Queen Elizabeth Hospital, Hong Kong.
Enrollment commenced for the TaurusTrio™ multi-center clinical trial in China for aortic valve regurgitation treatment.
MonarQ TTVR System achieved successful first-in-human implantation in the U.S.
HighLife multi-center clinical trial investigator coordination meeting held at the Chengdu Valve Conference.
Spearheaded the establishment of the Suzhou Interventional Medical Technology Innovation Consortium.
DCwire™ microguidewire and NRCoil™ detachable coils approved for market launch in the neurointerventional field.
Global headquarters officially inaugurated.
TaurusAtlas Pro® Balloon Dilatation Catheter approved for market launch.
TaurusOne® and TaurusElite® expanded with new AV21 specifications approved.
Clinical enrollment completed for TaurusTrio™, TaurusNXT®, and GeminiOne®. Exclusive distribution agreement signed with Nuanyang Medical for mesh stents.
Partner JenaValve fully acquired by Edwards Lifesciences.
Recognized as a national-level "Specialized and Innovative Little Giant" enterprise.
Approved as the Jiangsu Provincial Engineering Research Center for Structural Heart Disease Medical Devices.
Zhiweixin Medical opened in Changzhou, Jiangsu.
Jialin Biotech commenced operations in Linxia, Gansu.
![[list:title]](/template/en/static/img/common/arrow_right.png){kind=icon}
The National New Products Program of the Ministry of Science and TechnologyScientific and Technological Achievement Transformation Project in Jiangsu ProvinceJiangsu Medical Device Research Center for Structural Heart DiseasesScience & Technology Special Fund (Key R&D) Program in Jiangsu ProvinceEligible Foreign-funded R&D Center in Jiangsu ProvinceIndustrial Enterprise Quality Credit A Grade Enterprise in Jiangsu ProvincePrivate Science and Technology Enterprise in Jiangsu ProvinceChina Unicorn EnterpriseSuzhou Municipal Unicorn-oriented EnterprisePotential Landmark Company of the Biomedicine and Health Industry in SuzhouGusu Innovation and Entrepreneurship Leading Talent ProgramJinji Lake Double Hundred Talents ProgramOutstanding Contribution to Suzhou Industrial Park Economic DevelopmentHQ Enterprise based in Suzhou Industrial ParkTechnology Enterprise Listing Award in Suzhou Industrial Park
